Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 243.1% in February

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 333,800 shares, an increase of 243.1% from the January 31st total of 97,300 shares. Currently, 6.0% of the company’s shares are sold short. Based on an average daily volume of 1,590,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $40,000. Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $66,000. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals in the fourth quarter valued at $72,000. Northern Trust Corp acquired a new stake in Tonix Pharmaceuticals during the 4th quarter worth about $162,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at $526,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock opened at $8.18 on Friday. Tonix Pharmaceuticals has a twelve month low of $7.86 and a twelve month high of $1,244.80. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $15.29 million, a PE ratio of 0.00 and a beta of 2.07. The firm has a fifty day simple moving average of $24.99 and a 200-day simple moving average of $22.36.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.